Form 4: Castle Biosciences CFO Frank Stokes Reports Stock Transactions

Castle Biosciences' Chief Financial Officer, Frank Stokes, has reported multiple transactions involving the company's stock, including the vesting and sale of restricted stock units.

Summary

• Frank Stokes, the Chief Financial Officer of Castle Biosciences, has filed a Form 4 detailing several transactions.
• On December 9, 2024, Mr. Stokes acquired 14,617 shares of common stock through the vesting of restricted stock units and disposed of 6,571 shares at a price of $30.91.
• On December 10, 2024, he acquired 2,000 shares and 6,169 shares through vesting of restricted stock units and disposed of 900 shares and 2,773 shares at a price of $29.63.
• These transactions resulted in a net change in his holdings of common stock and restricted stock units.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing detailing stock transactions by an executive. It does not indicate any positive or negative sentiment.

Industry Context

Form 4 filings are a standard part of regulatory compliance for company insiders, providing transparency into their trading activities. These filings are common and expected.

Comparison to Industry Standards

• Form 4 filings are a standard practice for all publicly traded companies in the US.
• The transactions reported are typical for executives who receive stock-based compensation.
• The vesting schedules and sale of shares are consistent with common practices in the industry.

Stakeholder Impact

• The transactions may have a minor impact on the stock price due to the sale of shares by an insider.

Key Dates

Keywords

Form 4, Castle Biosciences, Frank Stokes, CFO, Stock Transactions, Restricted Stock Units, Vesting, Share Sales